On Monday, Definium Therapeutics announced topline data from a Phase 3 trial of its LSD candidate (DT120) for major depressive disorder (MDD). Reaction to the topline has been broadly positive, with the company’s stock price appreciating sharply on the news and Definium announcing plans to raise $700M in fresh capital. Following our reporting of the breaking news earlier this week…
